Evidence map›Paper›PMID 18164144›Full record

Trial reportDrug and alcohol dependence2008

Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform.

Joy M Schmitz, Marc E Mooney, F Gerard Moeller, Angela L Stotts, Charles Green, John Grabowski

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 6 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 6 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Dopamine agonists for the treatment of cocaine dependence.The Cochrane database of systematic reviews · 2015
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Joy M SchmitzDepartment of Psychiatry and Behavioral Sciences, University of Texas, Houston, TX 77030, USA. Joy.M.Schmitz@uth.tmc.edu
Marc E Mooney
F Gerard Moeller
Angela L Stotts
Charles Green
John Grabowski
University of Houston · USCenter for Clinical Research (United States) · USUniversity of Minnesota · USUniversity of Minnesota, Duluth · US

Funding

Translational MR Imaging in Cocaine Pharmacotherapy DevelopmentP50DA009262 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LANE, SCOTT D · 1994 to 2014
$26.9M
Cognitive-enhancing DA Medications for Cocaine DependenceR01DA030787 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LANE, SCOTT D, SCHMITZ, JOY MARIE · 2010 to 2014
$1.9M
Serotonin, Impulsivity, and Substance AbuseK02DA000403 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MOELLER, FREDERICK GERARD · 2000 to 2011
$1.2M
Combination Pharmacotherapy for Nicotine DependenceK01DA019446 · NIDA · UNIVERSITY OF MINNESOTA · PI MOONEY, MARC E · 2006 to 2010
$583k
NIDA NIH HHS K01-DA-019446NIDA NIH HHS K02-DA00403NIDA NIH HHS P50 DA009262NIDA NIH HHS P50-DA-9262NIDA NIH HHS R01 DA030787
6 · The paper itself

Abstract

backgroundThe dopamine precursor levodopa has shown some, albeit relatively weak, promise in treating cocaine dependence. This study sought to identify the most appropriate behavioral therapy platform for levodopa pharmacotherapy by evaluating its effect when administered in combination with behavioral platforms of varying intensities.

methodA total of 161 treatment-seeking cocaine dependent subjects received sustained release levodopa/carbidopa (400/100mg bid, Sinemet) or placebo delivered in combination with Clinical Management (ClinMan); ClinMan+cognitive behavioral therapy (CBT); or ClinMan+CBT+voucher-based reinforcement therapy (VBRT) in a 12-week randomized, placebo-controlled, double-blind (for medication condition) trial. Medication compliance was monitored with riboflavin (100mg/capsule) and the Medication Event Monitoring System. Protocol compliance was addressed in weekly, 10-min nurse-delivered ClinMan sessions. Weekly, 1-h CBT sessions focused on coping skills training. VBRT (with escalating reinforcer value) provided cash-valued vouchers contingent on cocaine-negative urine toxicology results. Urine benzoylecgonine assays collected thrice-weekly were analyzed by intention-to-treat criteria using generalized linear mixed models.

resultsLevodopa main effects were found on all outcome measures of cocaine use. Contrasts testing the levodopa-placebo difference within each behavioral platform found reliable effects, favoring levodopa, only in the VBRT platform. Levodopa treatment with vouchers produced higher proportions of cocaine-negative urines and longer periods of consecutive abstinence compared to other treatment combinations.

conclusionThis is the first study to find a significant treatment effect for levodopa and, in doing so, to demonstrate that the magnitude of this effect is dependent upon conditions of the behavioral therapy platform. The data support use of levodopa with abstinence-based reinforcement therapy as one efficacious combination in cocaine dependence disorder treatment.

Indexed as

AdultCocaine-Related DisordersCognitive Behavioral TherapyCombined Modality TherapyDiagnostic and Statistical Manual of Mental DisordersDopamine AgonistsDouble-Blind MethodFemaleHumansLevodopaMalePatient Acceptance of Health CarePatient ComplianceRetention, PsychologySeverity of Illness IndexDopamine AgonistsLevodopa

Identifiers

PMID18164144
PMCPMC2293271
OpenAlexW2069296272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.